Travere Therapeutics, Inc. TVTX

Updated: 11 Jun 2026

NASDAQ | Biotech | Rare disease biopharmaceuticals

No signal published yet

We already track Travere Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Travere Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Rare disease biopharmaceuticals
We're already tracking Travere Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On June 4, 2026, the company presented long-term Phase 3 DUPLEX study data showing sustained proteinuria reductions with FILSPARI in FSGS patients. Additionally, on June 2, 2026, Travere entered an exclusive licensing agreement with Everest Medicines to develop and commercialize civorebrutinib for rare kidney diseases outside of certain Asian markets.

What Firelda Watch includes for Travere Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Travere Therapeutics, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Black Mammoth Metals Corp
BMM
NEUTRAL
Crustal Resources B
HOLD
Crustal Minerals
CRUST B
NEUTRAL
Bioarctic
BIOA B
BUY
Swedish Orphan Biovitrum AB (publ)
SOBI
HOLD

Biotech

More companies in this sector

Want to follow Travere Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Travere Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Travere Therapeutics, Inc. TVTX
Travere Therapeutics — follow and we'll monitor it
Follow Travere Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.